Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer.

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) effectively at boost the immune system; however, they may cause immune-related ...

The tests have not been approved by federal regulators, but that hasn’t stopped patients from wanting them — and doctors from worrying. By Nina Agrawal In the spring of 2021, the cancer field was ...

Christy Houvouras exercises daily, eats right and has smoked fewer than 20 cigarettes in her lifetime. That’s why she was shocked when she was diagnosed with lung cancer at just 36 years old in July. ...

For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a ...

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...

Cancer dominates the drug development pipeline, but industry has paid little attention over the years to cancer cachexia — the complex weight-loss syndrome that accounts for 20–30% of cancer deaths.

Kerstin Haase is in the Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK. Mariam Jamal-Hanjani is in the Cancer Research UK Lung ...

America’s cancer research system, which has helped save millions of lives, is under threat in one of its most productive moments. Credit... Supported by By Jonathan Mahler Rachael Sirianni first ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (ARTL) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to ...